Skip to main content

High-Dose PPI Plus Aspirin Reduced Esophageal Cancer Risk

The combined use of aspirin and a high-dose proton pump inhibitor (PPI) appears to offer protection against the development of esophageal cancer in high-risk individuals, according to new findings presented at the 2018 American Society of Clinical Oncology Annual Meeting (abstract LBA4008). This strategy reduced the risk of developing high-grade dysplasia or progression to malignancy, and delayed death from any cause in people with Barrett esophagus.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino